|
|
Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma |
Tie-Jun Huang, Bi-Jun Huang, Qi-Wan Liang, Chu-Wen Huang and Yan Fang |
Guangzhou, China
Author Affiliations: Department of Nuclear Medicine, Second Municipal Hospital of Shenzhen, Shenzhen 518035, China (Huang TJ); Research Department, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China (Huang BJ, Liang QW, Huang CW and Fang Y)
Corresponding Author: Bi-Jun Huang, MD, Research Department, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China (Tel: 86-20-87343178; Fax: 86-20-87343146; Email: hbj26@hotmail.com) |
|
|
Abstract BACKGROUND: Molecular cytogenetics of oncogene HER-2 amplification in primary hepatocellular carcinoma (HCC) is still unknown. The aim of this study was to investigate the frequency of HER-2 oncogene amplification in primary HCC and its relations to clinicopathological parameters and prognosis.
METHODS: Forty-two surgical samples from patients with primary HCC were detected for their HER-2 oncogene amplification. The number of chromosome 17 and their ratio were tested by dual fluorescence in situ hybridization (FISH) technique, and then the correlations between HER-2 amplification, clinicopathological characteristics and prognosis were analyzed statistically.
RESULTS: HER-2 oncogene amplification was detected in 9 (21.4%) of the 42 primary HCCs, including 4 patients with high copy (HC) (9.5%) and 5 patients with low copy (LC) (11.9%). HER-2 amplification was associated significantly with tumor size and postoperative survival time of HCC patients (P<0.05), and the presence of HER-2 gene amplification was correlated with postoperative relapse (P=0.257), but not related to sex, age, AFP level, HBV infection, histopathological grading and clinical staging of HCC patients (P>0.05). The HER-2 oncogene copy was examined in 31 (73.8%) of the 42 primary HCCs, consisting of 9 patients with HER-2 amplification (21.4%) and 22 patients with aneuploidy (52.4%). No significant relations were observed between the HER-2 oncogene copy, patient sex, tumor size, histopathological grading, clinical staging, postoperative relapse and survival time (P>0.05); but the HER-2 oncogene copy was correlated significantly to age, AFP level and HBV infection (P<0.05).
CONCLUSIONS: There are a lower frequency of HER-2 oncogene amplification and a higher frequency of chromosome 17 aneuploidy in primary HCC. HER-2 oncogene amplification may be involved in the development and progression of large HCC in some patients, and seems to be a valuably independent prognostic factor predicting the recurrence and poor survival in patients with large HCC.
|
|
|
|
|
Cite this article: |
Huang TJ,
Huang BJ,
Liang QW,
et al.
Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int
2004;
3(1):
62-68. DOI:
|
|
|
|
URL: |
http://dx.doi.org/ OR http://www.hbpdint.com/EN/Y2004/V3/I1/62 |
|
|
|